1. Scrip
  2. >>Therapy Areas
  3. >>Genitourinary

Novartis Bookends October With Two IgAN Successes

 
• By Elizabeth Cairns

A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.    

Novartis HQ
• Source: Novartis

Two out of three ain’t bad, especially when the third is still in play. A hit in Phase III for Novartis AG’s second IgA nephropathy (IgAN) candidate, atrasentan, slots neatly next to the similar showing of iptacopan in the same disease disclosed at the start of the month.

Key Takeaways
  • Atrasentan follows Novartis’s in-house iptacopan with a top-line hit in IgA nephropathy

Iptacopan was developed by Novartis itself, but atrasentan was bought in, via the $3.2bn acquisition of Chinook Therapeutics Inc....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Still Looking For A Gene Therapy Hit, Syncona Backs Purespring In IgA Nephropathy Market

 
• By Andrew McConaghie

Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.

REGENCY Dandy for Roche In Lupus Nephritis

 
• By Elizabeth Cairns

Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.    

AstraZeneca Believes Size Matters In Amyloidosis

 
• By Elizabeth Cairns

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.    

More from Therapy Areas

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.